Chardan Capital Lowers Cognition Therapeutics (NASDAQ:CGTX) Price Target to $4.00

Cognition Therapeutics (NASDAQ:CGTX) had its target price dropped by stock analysts at Chardan Capital from $8.00 to $4.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other equities research analysts have also recently weighed in on CGTX. Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. HC Wainwright cut their target price on Cognition Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, March 24th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $6.13.

Cognition Therapeutics Stock Performance

NASDAQ CGTX opened at $0.30 on Thursday. The stock has a 50 day moving average price of $0.40 and a 200-day moving average price of $0.52. Cognition Therapeutics has a one year low of $0.28 and a one year high of $2.95. The company has a market capitalization of $18.59 million, a P/E ratio of -0.31 and a beta of 1.00.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, equities analysts predict that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BIOS Capital Management LP bought a new stake in shares of Cognition Therapeutics during the 4th quarter worth approximately $4,208,000. Sigma Planning Corp increased its stake in Cognition Therapeutics by 211.6% in the fourth quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after purchasing an additional 417,300 shares during the period. Voss Capital LP bought a new stake in shares of Cognition Therapeutics during the fourth quarter worth $351,000. CM Management LLC boosted its stake in shares of Cognition Therapeutics by 100.0% during the first quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $168,000 after purchasing an additional 200,000 shares during the period. Finally, Geode Capital Management LLC increased its stake in Cognition Therapeutics by 8.9% in the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock worth $247,000 after buying an additional 28,705 shares during the period. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.